Radha Rangarajan got to thinking about an idea to fight malaria from her research on knocking out a gene of the disease-causing parasite, Plasmodium. This was while she was a post-doc fellow at the Harvard School of Public Health. Deleting the gene seemed a good approach, but it wasn’t easy to figure out what to do next. That led her to leave academia to learn the ropes of drug discovery in the pharma industry. Eight-odd years later, in 2011, she founded Vitas Pharma in Hyderabad, aiming to tackle multi-drug-resistant bacterial infections, a key threat to health, through next-generation antibiotics.